Opexa Therapeutics
Get Full AccessDescription
- Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Companys leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.Opexas mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
-
Headquarters:2635 Technology Forest Boulevard , The Woodlands, Texas, United States
More -
Phone Number: +1 281-775-0600
-
Website: https://www.opexatherapeutics.com
-
Employees:24
-
Revenue:$10 - 50M
-
Legal Name:Opexa Therapeutics
-
Opexa Therapeutics's Social Media
-
Is this data correct?
-
| NAICS Code: 999990 |
Show More
Frequently Asked Questions regarding Opexa Therapeutics
-
Where are Opexa Therapeutics's Headquarters?
Opexa Therapeutics's Headquarters are in 2635 Technology Forest Boulevard ,The Woodlands,Texas,United States
-
What is Opexa Therapeutics's phone number?
Opexa Therapeutics's phone number is +1 281-775-0600
-
What is Opexa Therapeutics's official website?
Opexa Therapeutics's official website is https://www.opexatherapeutics.com
-
What is Opexa Therapeutics's Revenue?
Opexa Therapeutics's revenue is $10 - 50M
-
What is Opexa Therapeutics's NAICS code?
Opexa Therapeutics's NAICS code is 999990
-
How many employees are working in Opexa Therapeutics
Opexa Therapeutics has 24 employees
-
What is Opexa Therapeutics's Industry?
Opexa Therapeutics is in the industry of Biotechnology
-
Who is Opexa Therapeutics's Owner And Operator?
Opexa Therapeutics's Owner And Operator is April Bell

